Hungarian pharmaceutical company Gedeon Richter on Wednesday said it signed a strategic research collaboration and option-to-license agreement with Swiss biotech company FimmCyte. Richter said the partnership aims to advance the development of FimmCyte's FMC2 antibody for the treatment of endometriosis. The parties have negotiated an exclusive and worldwide license agreement for the future development and […]